Skip to main content
. 2017 May 24;8(46):81285–81294. doi: 10.18632/oncotarget.18150

Figure 4. Costs of patients related to CYP3A5 genotype and different immunosuppressors.

Figure 4

Participants’ cost of immunosuppressive agents of different CYP3A5 genotypes. NS: not significant, *: p < 0.05, **: p < 0.01, ****: p < 0.0001, Error bars in graphs indicates SEM.